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PGRN and its derived engineered protein, Atsttrin, were reported to antagonize TNFa and protect
against inﬂammatory arthritis [Tang, W. et al. (2011) The growth factor progranulin binds to TNF
receptors and is therapeutic against inﬂammatory arthritis in mice. Science 332 (6028) 478–484].
Here we found that PGRN level was also signiﬁcantly elevated in skin inﬂammation. PGRN/ mice
exhibited more severe inﬂammation following induction of oxazolone (OXA). In contrast, recombi-
nant Atsttrin protein effectively attenuated inﬂammation in mice dermatitis model. In addition, the
protective role of PGRN and Atsttrin in dermatitis was probably due to their inhibition on NF-jB sig-
naling. Collectively, PGRN, especially its derived engineered protein, Atsttrin, may represent a poten-
tial molecular target for prevention and treatment of inﬂammatory skin diseases.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Contact dermatitis is a common inﬂammatory skin disorder
characterized by pruritic skin lesions, immunodysregulation and
disrupted epidermal barrier function. Moreover, it is a commonly
used model system to evaluate potential therapies for psoriasis
and atopic dermatitis [1,2]. It is known that TNF-a plays a detri-
mental role in various inﬂammatory diseases [3]. To date, anti-
TNF therapy has been used in clinic for autoimmune inﬂammatory
diseases including psoriasis, which has been proved to be effective
in some of these patients [4,5].
PGRN is a multi-functional growth factor, and plays a critical
role in various physiological and disease processes such as wound
healing [6], tumorigenesis [7], chondrogenesis [8] and inﬂamma-
tion [9–13]. PGRN is expressed in epidermis, and is also involved
in skin repair and some skin diseases [6,14]. Recently, we reported
that PGRN antagonized TNF-a and exhibited anti-inﬂammatory
function in inﬂammatory arthritis models [3,11,12,15]. Herein weexamined the expression pattern of PGRN in skin of human and
mice under physiological and inﬂammation conditions, and deter-
mined the potential therapeutic function of PGRN, specially its de-
rived recombinant Atsttrin, in inﬂammatory skin diseases using
oxazolone-induced (OXA) contact dermatitis models.
2. Materials and methods
2.1. Mice
All animal studies were performed in accordance with institu-
tional guidelines and approval by the Institutional Animal Care
and Use Committee of New York University. The generation and
genotyping of C57BL/6 background PGRN/ mice have been de-
scribed previously [10]. 2-Month old WT and PGRN/ mice were
used for these experiments.
2.2. Preparation of Atsttrin protein
The generation and puriﬁcation of Atsttrin has been reported
previously [11,12]. Brieﬂy, the appropriate plasmid pGEX-Atsttrin
was transformed into Escherichia coli DE3 for expression of GST fu-
sion Atsttrin. Fusion protein was afﬁnity-puriﬁed on glutathione-
agarose beads as described before [16] with slight modiﬁcation.
The engineered proteins were digested with Factor Xa and the
supernatant was collected. Following the removal of Factor Xa by
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proteins was determined by SDS–PAGE.
2.3. Chemical-induced dermatitis mice models
OXA induced contact dermatitis model were established as pre-
viously described with minor modiﬁcations [17]. Brieﬂy, mice were
sensitized by a single application of 50 ll of 1.5% OXA (Sigma, MO,
USA) in ethanol on the dorsal skin 7 days before challenge. Then
two experiments were performed as follows.
2.3.1. Experiment 1
To testify the role of PGRN deﬁciency in dermatitis develop-
ment, the the inner and outer surfaces of right ear from WT and
PGRN/ mice were challenged with 20 ll of 1% OXA in a mixture
of acetone and olive oil (4:1), while left ear with mere acetone and
olive oil (4:1) as vehicle control (VEH) every other day for 7 days
and ear thickness of each group was measured every day with a
micrometer (Mitutoyo, Kanagawa, Japan). Thereafter, ear draining
lymph nodes and ear lobes were collected from both WT and
PGRN/ groups for further analysis. 10 mice were used for each
group of all this set of experiments.
2.3.2. Experiment 2
To verify the therapeutic role of Atsttrin for contact dermatitis,
the right ear of WT mice were challenged with OXA as mentioned
in experiment 1 every other day for 14 days, during which time
PBS or Atsttrin (2.5 mg/kg body weight) were delivered through
intraperitoneal injection every 3 days and ear thickness was mea-
sured every other day. Afterwards, ear lobes were collected from
both treatment groups for further analysis. 7 mice were used for
each group of all this set of experiments.
2.4. Real-time RT-PCR
Total RNA was extracted from ear tissue of each indicated
experimental group using an RNeasy kit (Qiagen, Valencia, CA,
USA). Reverse transcription was performed using a RT-for-PCR kit
(Qiagen, Valencia, CA) following the manufacturer’s protocol.
Reactions were performed in a 20-ll SYBR Green PCR volume in
a 96-well optical reaction plate formatted in the 7300 Sequence
Detection System (Applied Biosystems, Foster City, CA, USA).
Sequence-speciﬁc primers in the present study are synthesized
as follows: 50-AATCTCACAGCAGCACATCA-30 and 50-AAGGTGCTCA-
TGTCCTCATC-30 for IL-1b; 50-CCTTCCTACCCCAATTTCCAAT-30 and
50-GCCACTCCTTCTGTGACTCCAG-30 for IL-6; 50-AAT GCT GAC TAT
GGC TAC AAA A-30 and 50-AAA ACT GAT GCG TGA AGT GCT
G-30 for COX-2; 50-ACA GGAGGGGTTAAAGCTGC-30 and
50-TTGTCTCCAAGGGACCAGG-30 for iNOS; 50-TGGTGGAGCAGCAA-
GAGCAA-30 and 50-CAGTGGACAGTAGACGGAGGAAA-30 for PGRN;
50 TACAAGCTGGCTGGTGGGGA-30 and 50-GTCGCGGGTCTCAG-
GACCTT-30 for NF-jB2; 50-AGAACATCATCCCTGCATCC-30 and 50-
AGTTGCTGTTGAAGTCGC-30 for GAPDH. The presence of a single
speciﬁc PCR product was veriﬁed by melting curve analysis and
for each gene, the experiments were repeated three times.
2.5. Western blotting
Total ear extracts from each experimental and control group
were homogenized and proteins were collected. Proteins were re-
solved on a 10% SDS–polyacrylamide gel and electroblotted onto a
nitrocellulose membrane. After blocking in 5% non-fat dry milk in
Tris buffer-saline–Tween 20 (10 mM Tris–HCl, pH 8.0; 150 mM
NaCl; and 0.5% Tween 20), blots were incubated with polyclonal
anti-PGRN, anti-phosphorylated IjB-a (pIjB-a) or anti-iNOS
(diluted 1:1000) antibody for 1 h. After washing, the secondaryantibody (horseradish peroxidaseconjugated anti-rabbit immuno-
globulin; 1:2000 dilution) was added, and bound antibody
was visualized using an enhanced chemiluminescence system
(Amersham Life Science, Arlington Heights, IL, USA).
2.6. Histology
The mice ear specimens were ﬁxed in 10% Formalin, dehy-
drated, cleared with dimethylbenzene, and then embedded in ole-
ﬁn. At least 4 consecutive 6-lm sections were obtained from the
sagital planes, and stained using hematoxylin and eosin (HE) for
routine morphologic analysis. The epidermal thickess was exam-
ined using OsteoMeasure software (OsteoMetrics, Inc., Decatur,
GA).
2.7. Immunohistochemistry
Seven skin samples were harvested from the legs of randomly
selected psoriasis patients with plaque-stage psoriasis vulgaris,
who received treatment at Department of Dermatology, Qilu Hos-
pital, Shandong University from January 2011 to December 2011.
Seven samples of normal skin tissues were collected from the same
anatomic location of healthy volunteers from the Department of
Plastic Surgery of Qilu Hospital. The study was approved by the
Ethical Committee of Qilu Hospital of Shandong University and a
written inform consent was obtained from each participant in this
experiment. Special care was taken to minimize stress on the tissue
when performing the biopsy. All samples were ﬁxed for 48 h in 10%
formalin and prepared as reported before [14]. Besides, ear tissues
from indicated experimental groups were collected, and prepared
as described previously [18,19]. The skin samples were then incu-
bated with anti-PGRN or anti-p-IjB-a polyclonal antibody (1:100
dilution; Santa Cruz Biotechnology) at 4 C overnight, followed
by incubation with a horseradish peroxidase-conjugated secondary
antibody for 60 min at room temperature. The signal was detected
using the Vector Elite ABC Kit (Vectastain; Vector).
2.8. Flow cytometry
Single-cell suspensions from the cervical draining lymph nodes
were prepared through isolating LN cells by crushing the nodes
and ﬁltering through a 70-lm strainer (BD Biosciences). Antibody
PerCP-Cy5-conjugated anti-CD4 was used for surface staining. For
intracellular staining of Foxp3, cells were ﬁxed and permeabilized
with a commercial Foxp3 staining kit (eBiosciences) and the cells
were stained with Alexa Fluor 647-conjugated anti-Foxp3 (BD
Biosciences).
2.9. Statistical analysis
The data were expressed as mean ± standard deviation (S.D.).
The Statistical Package for Social Sciences version 17.0 (SPSS Inc,
Chicago, IL) was used for standard statistical analysis including
one-way ANOVA and Student’s t-test. Statistical signiﬁcance was
achieved when a value of P < 0.05.3. Results
3.1. Progranulin (PGRN) expression was upregulated in inﬂammatory
skin
To examine the expression pattern of PGRN in skin, immunohis-
tochemistry was performed in skin samples from normal control
and psoriasis patients. Fig. 1A showed that PGRN was detectable
in normal skin and its level was elevated in epidermis of psoriasis
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was particularly expressed in extracellular matrix of skin in psori-
asis (Fig. 1A, panel d). To examine the expression proﬁling of PGRN
in skin inﬂammation of mice, OXA-induced dermatitis model was
established in WT mice as described in experiment 1, and immu-
nohistochemistry was performed. Fig. 1B revealed that PGRN
expression was dramatically enhanced in skin after induction of
dermatitis. To further verify this alteration of PGRN expression,
we performed real-time PCR and Western blotting for VEH and
OXA induced WT ears (n = 3, respectively), and both RNA
(Fig. 1C) and protein levels of PGRN (Fig. 1D) were dramatically
elevated in skin of dermatitis.
3.2. Deﬁciency of PGRN led to exaggerated skin inﬂammation in mice
contact dermatitis model
To investigate the role of PGRN in skin inﬂammation, OXA-in-
duced dermatitis model was established in WT and PGRN/mice
as described in experiment 1. Both genotypes exhibited remark-
able increase of ear thickness following stimulation of OXA, but
the ear thickness in PGRN/ group was signiﬁcantly larger than
WT littermates in dermatitis (Fig. 2A). The ear samples were also
assessed via histology and the result revealed that while there
was no obvious difference between the two genotypes in VEH
groups, PGRN/mice exhibited thicker epithelium and increased
inﬁltration of inﬂammatory cells than WT mice in OXA-induced
mice models (Fig. 2B). Real-time PCR assay of ears indicated there
was no signiﬁcant difference in the levels of inﬂammatory param-
eters, including IL-1b, IL-6, COX-2 and iNOS between WT and
PGRN/mice in VEH control groups, while deﬁciency of PGRN re-Fig. 1. The expression pattern of PGRN in skin of human and mice. (A) PGRN was expr
elevated in skin of psoriasis patients (panel c) and high-resolution analysis showed that P
normal control (n = 7) and psoriasis patients (n = 7) were collected and were stained wit
representative pictures are shown. (B) PGRN expression in WT mice skin induced by v
elevated in oxazolone-induced dermatitis model (OXA) (panel c) and high-resolution anal
(C) Relative level of PGRN in ear tissue of WT mice stimulated with vehicle or oxazolone,
WT mice with challenge of vehicle or oxazolone (n = 3, respectively), assayed by Westersulted in signiﬁcantly higher levels of all those molecules in OXA-
induced dermatitis model (Fig. 2C–F). iNOS is reported to mediate
inﬂammatory reaction in OXA-induced dermatitis models [20]. To
further determine the effect of PGRN deﬁciency on the induction of
iNOS in skin inﬂammation, Western blotting assay for iNOS was
then performed. Fig. 2G indicated that iNOS was undetectable in
ear homogenates of both genotypes without OXA challenge
(n = 1, respectively), while PGRN/ ear expressed dramatically
higher level of iNOS than WT mice following OXA induction
(n = 3, respectively). In addition, cervical lymph node cells from
dermatitis models were harvested, and ﬂow cytometry was per-
formed to compare regulatory T cell (Treg) development in both
genotypes. The result demonstrated that Treg/total T cell ratio
was dramatically lower in PGRN/ group (Fig. 2H), impling the
defect of Treg development in skin inﬂammation.
3.3. Atsttrin attenuated skin inﬂammation in mice contact dermatitis
model
PGRN and its derived engineered protein, Atsttrin, protected
against inﬂammatory arthritis in mice models [12]. To assess
whether Atsttrin also has therapeutic effect in inﬂammatory skin
disease, OXA-induced dermatitis model was established in WT
mice and treated with PBS or Atsttrin as described in experiment
2. Ear thickness was measured and Atsttrin treatment group dis-
played signiﬁcantly less increase of ear thickness than PBS group
(Fig. 3A). Histological assessment of ear samples showed that
thickening of epithelium and inﬁltration of inﬂammatory cells
were also inhibited in Atsttrin treatment group (Fig. 3B and C).
Moreover, RNA was collected from ear tissue of both treatmentessed inside cells of normal human skin (panels a and b). Its expression level was
GRN was particularly detectable in extracellular matrix (panel d). Skin samples from
h anti-PGRN antibody (brown), then counterstained with methyl green (green), and
ehicle (VEH) (panels a and b), assayed by immunohistochemistry. PGRN level was
ysis showed that PGRNwas particularly distributed in extracellular matrix (panel d).
assayed by real-time PCR. ⁄⁄⁄P < 0.005. (D) Expression level of PGRN in ear tissue of
n blotting. Bars = 40 lm.
Fig. 2. Loss of PGRN resulted in more severe inﬂammation in oxazolone-induced dermatitis. (A) Ear thickness was dramatically increased in WT and PGRN/ mice after
induction of oxazolone compared with vehicle (VEH) groups, while deﬁciency of PGRN led to signiﬁcantly increased ear thickness (n = 10 for each group). ⁄⁄⁄P < 0.005 vs. WT
dermatitis group. (B) PGRN/ mice exhibited more severe thickening of epidermis and inﬁltration of inﬂammatory cells than WT mice, assayed by HE staining. Scale bar,
50 lm. (C–F) RNA levels of inﬂammatory parameters including IL-1b, IL-6, COX-2 and iNOS were signiﬁcantly higher in ear tissue of PGRN/ mice than WT mice following
oxazolone induction, as measured by real-time PCR. The values are the mean ± S.D. of 3 independent experiments. ⁄P < 0.05, ⁄⁄P < 0.01 and ⁄⁄⁄P < 0.005 vs. WT group. (G)
Expression of iNOS in ear extracts of WT and PGRN/mice with challenge of oxazolone (n = 3, respectively) or vehicle (n = 1, respectively), assayed by Western blotting. (H)
Treg development in cervical lymph node of WT and PGRN/ mice in dermatitis model, detected by ﬂow cytometry. Numbers in red in the upper right quadrant represent
the Foxp3+ population as a percentage of CD4+ cells. Results are representative of 3 independent experiments.
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levels of inﬂammatory parameters IL-1b, IL-6, COX-2 and iNOS,
were signiﬁcantly lower in Atsttrin treatment group (Fig. 3D–G).
Total protein was also collected from ears of both PBS and Atsttrin
treatment group (n = 3, respectively), and Western blotting was
performed for iNOS level. As shown in Fig. 3H, Atsttrin treatment
markedly reduced iNOS protein level in dermatitis.
3.4. Deﬁciency of PGRN elevated, whereas recombinant Atsttrin
inhibited, the expression and activity of NF-jB signaling
It is known that PGRN and Atsttrin inhibited activation of NF-jB
signaling pathway in inﬂammatory arthritis models [12], together
with the reports that NF-jB signaling played a critical role in skin
inﬂammatory diseases [21], promoted us to determine whether
PGRN deﬁciency or treatment of Atsttrin affected NF-jB signaling
in OXA-induced dermatitis model. To investigate the potential ef-
fect of PGRN deﬁciency on NF-jB signaling in dermatitis, RNA ex-
tracts were collected from ears of both genotypes with or without
challenge of OXA in experiment 1, and the NF-jB2 level was mea-
sured using real-time PCR. As revealed in Fig. 4A, while there was
no signiﬁcant difference between two genotypes in control unin-
duced ears, NF-jB2 level was signiﬁcantly higher in ear tissue of
PGRN/mice thanWT group in OXA induced dermatitis. Further-
more, total proteins were collected from ears of experiment 1, and
a Western blotting was performed for examining the phosphory-
lated IjB (pIjB-a), which indicates the activity of NF-jB signalingpathway. Fig. 4B showed that pIjB-a was faint in VEH challenged
ear of both genotypes, while PGRN/ group exhibited dramati-
cally increased pIjB-a thanWT littermates in dermatitis. To exam-
ine the regulation of NF-jB signaling by Atsttrin, RNA extracts
were harvested from ear tissues of experiment 2, followed by
real-time PCR. Result indicated that Atsttrin signiﬁcantly reduced
NF-jB2 level compared with PBS treatment group in OXA-induced
dermatitis model (Fig. 4C). Moreover, immunohistochemistry for
pIjB-a was performed on ear sections of both treatment groups
in experiment 2. PBS group demonstrated strong signal of pIjB-a
in cytoplasm of cells in epidermis of dermatitis model, while this
was dramatically attenuated in Atsttrin group (Fig. 4D).
4. Discussion
PGRN and Atsttrin were reported to be therapeutic in inﬂamma-
tory arthritis in mice [12]. In addition, loss of PGRN increased the
susceptibility to collagen-induced inﬂammatory arthritis [12]. In
this study we used OXA-induced contact dermatitis model and
found that deﬁciency of PGRN also led to exaggerated skin inﬂam-
mation. Interestingly, Atsttrin, an engineered protein that is com-
prised of the three fragments of PGRN responsible for binding to
TNF receptors [12], attenuated the severity of skin inﬂammation
in contact dermatitis.
PGRN is reported to be secreted by epithelial cells and inﬂam-
matory cells of skin, and its level in skin is elevated in some path-
ological condition and skin trauma [14,22,23]. Here we found that
Fig. 3. PGRN-derived engineered protein Atsttrin attenuated skin inﬂammation in oxazolone induced dermatitis model. (A) Atsttrin treatment inhibited increase of ear
thickness in oxazolone-induced dermatitis. Ear thickness was measured every other day for 14 days and compared between PBS and Atsttrin treatment groups (n = 7,
respectively). (B and C) Atsttrin treatment attenuated thickening of epithelium and inﬁltration of inﬂammatory cells in dermatitis model, detected by HE staining. Scale bar,
50 lm. (D–G) Relative levels of IL-1b, IL-6, COX-2 and iNOS in PBS and Atsttrin treatment groups in dermatitis model, assayed by real-time RT-PCR. (H) Expression of iNOS in
ear extracts of PBS and Atsttrin treated mice in dermatitis model, assayed by Western blotting. Each experiment was repeated in triplicate, and the values are the mean ± S.D.
⁄P < 0.05, ⁄⁄P < 0.01 and ⁄⁄⁄P < 0.005 vs. PBS treatment group.
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mice dermatitis model, particularly in the extracellular matrix,
compared with normal controls. This is also consistent with the
previous report that PGRN level was dramatically elevated in the
patients with osteoarthritis or rheumatoid arthritis, and played a
protective role in the pathogenesis of arthritis [18]. Recently it
was reported that PGRN level was also signiﬁcantly elevated in
the patients with systemic lupus erythematosus [24]. It is specu-
lated that the elevation of PGRN expression in skin was secondary
to the increased inﬂammatory cytokines in particular TNF-a which
accelerated skin inﬂammation process, but the elevated level of
PGRN was still not sufﬁcient to neutralize the activities of such
inﬂammatory cytokines.
It is well-established that TNF-a acts as one of the dominant
factors in various skin inﬂammatory diseases [4,25]. Anti-TNF
agents have been used for treatment of psoriasis [26]. NF-jB sig-
naling is a key pathway for TNF-amediated inﬂammatory function
and plays a critical role in progression of skin inﬂammation [27–
29]. IL-1b, IL-6, COX-2 and iNOS are important downstream mole-
cules of NF-jB signaling pathway [30] and are assayed as inﬂam-
matory markers in dermatitis [31,32].We reported that PGRN
inhibited TNF-a mediated activation of NF-jB signaling in inﬂam-matory arthritis in mice [12]. In this study, we found deﬁciency of
PGRN enhanced, while treatment of Atsttrin effectively inhibited
the expression and activity of NF-jB signaling pathway, and af-
fected the levels of its downstream molecules in dermatitis mod-
els. This ﬁnding suggests the protective role of PGRN and Atsttrin
maybe through repressing activation of NF-jB signaling pathway.
Treg is known to ﬁght against dermatitis in various models [33].
We found that deﬁciency of PGRN led to fewer Foxp3-positive Treg
compared with WT littermates following OXA induction. In addi-
tion, PGRN was reported to selectively induce the differentiation
of Treg from naïve T cells in vitro [12]. These ﬁndings suggest that
the exaggerated inﬂammation seen in dermatitis of PGRN/mice
might be also due to the defect in Tregs differentiation in PGRN-
deﬁcient dermatitis model.
Collectively, PGRN plays a protective role in the development of
dermatitis, and its derived engineered protein, Atsttrin, may repre-
sent a promising therapeutic agent in treatment of inﬂammatory
skin diseases, including contact dermatitis and psoriasis.
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